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Abstract
Chronic musculoskeletal pain is a complex disorder that often causes physical and
psychological symptoms. While acute pain promotes healing of damaged tissue, chronic pain
is caused by long-term maladaptive changes that result in hyperexcitability of pain-signaling
neurons. Potassium channels have recently been implicated in pain syndromes because they
largely determine the characteristics for cell activation. The gene KCNS1 encodes for a
potassium channel alpha subunit, and a common single nucleotide polymorphism (SNP) in
this gene was recently correlated with more severe chronic neuropathic pain. Therefore, this
study explores the effects of this KCNS1 SNP on the symptomology of chronic
musculoskeletal pain and response to treatment with cognitive behavioral therapy (CBT) or an
educational control condition (EDU). The sample included 201 participants with chronic
musculoskeletal pain who provided saliva samples from which their DNA was extracted,
amplified, and sequenced to determine each participant’s KCNS1 genotype. Participants
answered questionnaires measuring physical pain symptoms and psychological suffering at
baseline and again following three months of treatment. At baseline, those homozygous for
the Val mutation were found to have reduced catastrophizing, lower total pain experience, and
greater mental functioning compared to their Val/Ile and Ile/Ile counterparts. Interestingly, all
participants improved to the same level of physical and psychological functioning after both
treatments regardless of genotype, with greater improvements seen in CBT compared to EDU
for all genotypes. Additionally, Ile/Ile individuals tended to improve more in psychological
domains, whereas Val/Ile individuals improved more physically. This suggests that KCNS1
genotypic variation can alter the symptomology of chronic musculoskeletal pain and that CBT
is an effective chronic pain treatment regardless of KCNS1 genotype.
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1. Introduction
Chronic pain is a complex sensory experience that typically involves both physical and
psychological symptoms. While acute pain is adaptive and even protective, chronic pain is the
result of long-term maladaptive changes within the central and peripheral nervous systems
that perpetuates the sensation of pain after the noxious stimulus has dissipated (Ji, Xu,
Strichartz, & Serhan, 2011). Chronic pain includes both musculoskeletal and neuropathic pain
that lasts for six months or longer, and research indicates the two may share some similar
underlying mechanisms (Ji et al., 2011). Musculoskeletal pain occurs following tissue injury
that elicits an inflammatory response involving a cascade of chemical signals that increase
sensitivity of the injured region in order to promote healing (Li et al., 2014). These
inflammatory mediators activate secondary messengers within the periphery that then signal
nociceptors in the central nervous system, resulting in the perception of pain. However, it
appears this inflammatory response can also stimulate long-term transcriptional and
translational changes within peripheral neurons to increase the signaling of pain pathways,
potentially resulting in a transition from an acute to a chronic pain state (Woolf & Costigan,
1999).
The shift from acute to chronic pain likely involves several biological mechanisms,
including peripheral and central sensitization, long-term potentiation, and windup, with
potential variations for chronic musculoskeletal versus chronic neuropathic pain (Ji et al.,
2011). Research suggests that while chronic neuropathic pain may be caused by long-term
maladaptive sensitization of nociceptors, chronic musculoskeletal pain may instead involve
prolonged stimulation of nociceptors (Costigan et al., 2010; Everill & Kocsis, 1999; Nielsen
& Henriksson, 2007). These processes may lower the activation thresholds for pain-signaling
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neurons and cause spontaneous and/or exaggerated neuronal firing in response to noxious
stimuli (Woolf & Costigan, 1999). This increased sensitivity and hyperexcitability may
maintain the sensation of pain without the appropriate stimulation because the nervous system
itself is now generating the painful signals via chemical mediators.
This dysfunction of the nervous system results in 76 million Americans experiencing
chronic pain syndromes every year (Zheng & Peltz, 2010). This clinical population
experiences reduced quality of life and costs taxpayers over $100 billion annually (Zheng &
Peltz, 2010). Despite the severity of this issue, the mechanisms underlying chronic pain
remain poorly understood and the available treatments tend to be problematic with regards to
long-term efficacy and abuse potential. Therefore, the present study seeks to augment current
knowledge with potential predisposing factors to susceptibility and treatment of chronic
musculoskeletal pain.
Current commonly available treatments for chronic pain present a rising health concern, as
they mostly rely on prescription opiates and non-steroidal anti-inflammatory drugs (NSAIDs)
without further intervention (King, Fraser, Boikos, Richardson, & Harper, 2014). Evidence
suggests that taking commonly prescribed NSAIDs, such as ibuprofen, may actually prolong
inflammation after injury by disrupting endogenous pro-resolving and/or anti-inflammatory
mechanisms (Ji et al., 2011). Furthermore, prescription opiates are commonly over-prescribed
and have high potential for abuse, representing significant health challenges and potentially
detrimental long-term effects (King et al., 2014). For example, prescription of all opioid
painkillers for chronic musculoskeletal pain doubled in the United States from 1980 to 2000,
and was also associated with increasing dosage, with prescription rates of the most potent
opiates actually quadrupling during this time period (King et al., 2014). Moreover, the recent
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opioid epidemic seen nationwide is a particular concern in Vermont, which was recently
referred to as “The New Face of Heroin” in an issue of Rolling Stone Magazine released in
April, 2014. The issue may be aggravated by the prescription practices of Vermont
physicians, as methadone-related deaths increased 400% from 2001 to 2006 alone and 60% of
methadone prescriptions were for the treatment of chronic pain (Madden & Shapiro, 2011). It
is therefore of the upmost importance to find effective, therapeutic treatments for chronic pain
without exacerbating health-related challenges as commonly occurs with current
pharmacologic treatments.
It has previously been reported that treatment with Cognitive Behavioral Therapy (CBT)
is effective at alleviating chronic pain symptoms, and so may represent an effective
alternative treatment option with reduced side effects for those with chronic musculoskeletal
pain (Bair, Wu, Damush, Sutherland, & Kroenke, 2008). Subsequently, the present study
seeks to explore factors that may affect the susceptibility and severity of chronic
musculoskeletal pain, as well as how they relate to successful psychotherapeutic treatment of
the disorder.
The huge phenotypic variation in chronic pain symptoms, coupled with the fact that not all
those who sustain a tissue injury develop such disorders, suggests multiple biological
mechanisms may be involved. Emerging evidence has emphasized the role of genetic
predispositions to chronic pain, and suggests up to 60% of the variability in the development
of chronic pain is heritable (Young, Lariviere, & Belfer, 2012). Due to the fact that neuronal
misfiring is involved in chronic pain symptoms, potassium channels are likely involved as
they largely determine the characteristics for neuronal cell activation (Costigan et al., 2010;
Richardson & Kaczmarek, 2000). Therefore, genes that encode for potassium channels could
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potentially alter the pain phenotypes seen in patients experiencing chronic pain by modulating
sensory neuron excitability. Subsequently, the present study focuses on the gene KCNS1,
which encodes for a potassium channel alpha subunit and is constitutively transcribed in
sensory neurons (Costigan et al., 2010; Richardson & Kaczmarek, 2000).
Research suggests this subunit is nonfunctional alone, but serves to modulate the
currents of potassium channels in sensory neurons when conjoined with other subunits
(Costigan et al., 2010; Richardson & Kaczmarek, 2000). For example, it was determined that
when combined with other subfamilies of potassium channel alpha subunits, KCNS1 inhibited
the firing of action potentials during maintained stimulation in excitable cells (Richardson &
Kaczmarek, 2000). Such modulatory effects on first-order sensory neurons suggest KCNS1
can influence the pain phenotypes that manifest as chronic pain syndromes (Costigan et al.,
2010; George et al., 2014; Richardson & Kaczmarek, 2000; Smolin, Karry, Gal-Ben-Ari, &
Ben-Shachar, 2012; Tsantoulas et al., 2012; Zheng & Peltz, 2010). This idea is further
supported by the fact that KCNS1 is substantially downregulated after injury in three distinct
chronic neuropathic pain models, including spared nerve, chronic constriction, and spinal
nerve ligation injuries (Costigan et al., 2010; Tsantoulas et al., 2012; Zheng & Peltz, 2010).
The fact that the expression of KCNS1 is reduced after nerve injury lends support to the
notion that this gene may be involved in neuropathic pain signaling, potentially implicating
the gene in other chronic pain disorders. In fact, recent literature suggests that variation in the
KCNS1 genotype can alter an individual’s sensitivity to neuropathic pain as well as their
susceptibility to developing chronic neuropathic pain syndromes (Costigan et al., 2010;
Young et al., 2012). Due to the potentially significant overlap between chronic pain disorders,
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these findings validate investigating the effect of genotypic variation of KCNS1 on pain,
suffering, and response to treatment in patients with chronic musculoskeletal pain.
Emergence of pain phenotypes associated with peripheral injuries appears to be altered
by a missense single nucleotide polymorphism (SNP) at the rs734784 KCNS1 allele that
results in a valine-to-isoleucine substitution (Costigan et al., 2010; George et al., 2014). This
mutation is quite prevalent, with approximately 50% of the population heterogeneous and 20%
homogeneous for this SNP, making it a clinically relevant gene to investigate (Costigan et al.,
2010). When this gene was examined in patients with chronic neuropathic pain, the valine
(Val) allele was associated with greater pain intensity in five different patient cohorts
(Costigan et al., 2010). Subsequent research found that the KCNS1 Val mutation was
associated with greater upper extremity disability and more frequent pain catastrophizing,
indicative of more fear-avoidance behaviors, and suggesting KCNS1 may affect more than
just the physical symptoms of pain (George et al., 2013). This indicates that KCNS1 genotype
may modify the prognosis of chronic pain, making our study particularly relevant as the effect
of KCNS1 has never before been examined in a chronic musculoskeletal pain population. The
present study will therefore investigate how genotypic variation in KCNS1 affects the pain
phenotypes in those with chronic musculoskeletal pain, as well as their response to treatment
with cognitive behavioral therapy (CBT) compared to a control educational materials mailing
program (EDU).

1. Methods
2.1 Participants
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The study sample comprised 201 male and female adults, ages 18 to 65, of any racial
or ethnic background concurrently enrolled in a chronic musculoskeletal pain study at the
University of Vermont’s MindBody Medicine Clinic (Table 1). Participants were recruited
from advertisements and flyers posted around the Burlington area as well as clinical referrals
from other physicians. The sample included patients with diagnoses of chronic back pain,
osteoarthritis, post-trauma pain, temporomandibular disorder, and fibromyalgia. Inclusion
criteria included: at least 1 year of chronic musculoskeletal, non-neuropathic pain, and a
subjective typical pain rating of at least 4 out of 10 (with 0 “no pain” to 10 “worst pain”) for
the preceding month. Exclusion criteria included malignancy, awaiting pain-related surgery,
involvement in pain-related ligation, an Axis I disorder (except for controlled mild to
moderate depression and anxiety), and severe personality disorders.

Table 1. Descriptive Statistics for Demographic Factors
Variable
Age
Gender
Female
Male
Race
White
Black or African American
Other
KCNS 1 Genotype (rs734784)
GG
AG
AA

Mean ± SD or Frequency
48.5 ± 13.6

Median (Min, Max) or %
50.5 (18, 81)

131
62

68%
32%

178
4
11

92%
2%
4%

34
73
86

18%
38%
45 %

2.2 Materials
Clinical and behavioral measures were self-administered at baseline and then again
following three months of treatment with either CBT or EDU. Participants responded to
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questionnaires in regards to their musculoskeletal pain. The McGill Pain Questionnaire was
used to assess how patients perceived and rated their typical pain intensity on a 0 to 10 scale
(with 0 “no pain” to 10 “worst pain”) (Melzack, 1975). Additionally, the Treatment Outcomes
in Pain Survey (TOPS) subscales SF-36 Physical Health Composite (PHC) and Total Pain
Experience (TPE) were used to evaluate several measures of physical functioning, including
bodily pain, pain symptoms, functional limitations, and perceived disability (Rogers, Wittink,
Ashburn, Cynn, & Carr, 2000). All of these scales are composite scores from multiple items
and range from 0 to 100.
Emotional functioning was also assessed using a TOPS subscale, the SF-36 Mental
Health Composite (MHC), which evaluates several domains including mental health and
emotional and social functioning, with composite scores ranging from 0 to 100 (Rogers et al.,
2000). Participant pain-related catastrophizing was also evaluated using either the Pain
Catastrophizing Scale (PCatS) (Sullivan, Weinshenker, Mikail, & Bishop, 1995) or the
Catastrophizing Subscale of the Coping Strategies Questionnaire (CSQ) (Lawson, Reesor,
Keefe, & Turner, 1990) were used. A total of five overlapping questions (5 out of 6 in CSQ
and 5 out of 13 in PCatS) were found in both of these questionnaires and were used in order to
compare the two scales. The scale ranges from 0 to 6 for CSQ and 0 to 4 for PCatS, so scores
were transformed to a scale of 0-100 and expressed as an average. Participant depression was
also assessed using the Beck Depression Inventory (BDI) questionnaire (Beck, Ward,
Mendelson, Mock, & Erbaugh, 1961). Subjects with BDI scores below 13 were considered
minimally depressed, 14-19 mildly depressed, 20-28 moderately depressed, and 29-63
severely depressed.
2.3 Procedure
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The University of Vermont’s institutional review board for human subjects approved
this study, and all subjects provided informed consent prior to participating. Subjects
underwent clinical evaluation and cognitive testing to determine their eligibility. Participants
were then randomized into either CBT intervention or a control educational condition. The
study design is summarized in Figure 1.

Figure 1. Study Design
Recruitment to MindBody Medicine Clinic for Group
CBT coping skills training
(N=201)

Assessment #1 – Baseline Assessment.
Screening and Informed Consent
Randomization stratified by pain and gender to one of
two conditions

Condition 1: Attention Control
(N=62)

Condition 2: 11 weeks of group CBT
(N= 124)

Assessment #2
(N=186)

The CBT intervention is referred to as Coping Skills Training and was developed
specifically for treatment of chronic pain. Typically, between 7-10 patients participate in each
group CBT session, and participants randomized to this condition attend weekly 90 minute
group sessions for 11 weeks and receive on-going feedback and encouragement.
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Details of Group Cognitive Behavioral Therapy - CBT
The purpose of this CBT intervention is to 1) reduce maladaptive coping skills, such
as catastrophizing, and 2) increase the ability of the patient to use adaptive strategies to cope
with their pain, including attention diversion and changes in activities. To apply CBT to a
pain management group program, a simplified gate control model of pain is used,
emphasizing to patients that pain is a complex and multifaceted experience involving thoughts,
feelings, and behaviors (Melzack & Wall, 1965). The coping strategies used here emphasize
skills patients can practice so as to better control their pain.
A. Changing Cognitions. Cognitive-restructuring is used to emphasize to patients the
relationship between their thoughts, feelings, and behavior. Such techniques help participants
to identify irrational and maladaptive thought patterns so that they can replace them with
more rational thoughts to better cope with their pain. Patients were also encouraged to engage
in calming self-statements to deal with severe pain.
B. Attention Diversion Methods. Patients are trained in three attention diversion
methods, including relaxation, imagery, and distraction. Relaxation training involves using
muscle tension signals as a cue to relax. Mini-practices, or brief relaxation methods, are used
to teach patients how to apply relaxation techniques during daily activities. Patients are also
taught to focus on pleasant imagery to aid their relaxation (Rosenstiel & Keefe, 1983). Finally,
distraction techniques emphasize focusing on physical and/or auditory stimuli.
C. Controlling Pain by Changing Activity Patterns. Activity-rest cycling and
pleasant activity scheduling are used to help patients reduce their pain and more effectively
increase their activity level (Houpt, Keefe, & Snipes, 1984; Keefe, 1982). Activity-rest
cycling involves patients identifying activities that cause them to overexert themselves and
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learning to break them up with periods of rest. Patients also identify pleasant activities they
enjoy and set and record weekly activity goals.

Details of Attentional Control Condition
Participants randomized to the control group receive 11 weekly mailings of
educational materials with information on the nature of pain. This includes pain physiology
and methods of maintaining a healthy lifestyle, emphasizing the importance of physical
activity and of weight control. However, the mailings do not specifically address the coping
strategies taught during CBT, nor do they provide feedback. For ethical reasons patients
randomized to the control group may enroll in CBT after completing the educational program
free of charge to ensure all participants are given adequate clinical treatment regardless of
randomization. This program has been described previously (Naylor, Helzer, Naud, & Keefe,
2002; Naylor, Keefe, Brigidi, Naud, & Helzer, 2008).

Genetic Analysis
Participants provided saliva samples from which their DNA was extracted following
typical guanidine hydrochloride extraction protocol with DNA STAT-60TM, amplified
according to standard polymerase chain reaction (PCR) protocol, and sequenced in order to
determine each participant’s genotype at the rs734784 KCNS1 allele. The extraction involves
homogenization of the DNA followed by phase separation, precipitate formation, and removal
of contaminants. The yield and purity of all samples are then tested using a NanoDrop TM
spectrometer, which measures nucleic acid concentrations. PCR amplification serves to
replicate the DNA so that it can be sequenced, and involves separating the DNA strands with
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heat and adding specific primers that bind to opposite strands, allowing for synthesis and
replication of the desired allele. Finally, the Qiagen PyroMark Q24 pyrosequencer used for
sequencing is highly susceptible to detecting SNPs and is therefore appropriate for this study.

After three months of intervention with either CBT or educational materials,
questionnaires were compared to evaluate patient levels of physical pain, psychological
suffering, and ability to cope with these pain symptoms. These data were used in order to
identify any significant differences within and between intervention groups according to
variations in KCNS1 genotype.

2.4 Statistical Analysis
This analysis used data from patients involved in a chronic musculoskeletal pain study
who had completed at least one baseline assessment. A regression analysis to control for age
and sex as covariates was conducted to characterize the baseline sample, and their interactions
with KCNS1 genotype were not found to be significant. After removing any participants for
missing data, the population means for each of the six clinical measures were determined.
Any scores greater than three standard deviations from the mean were determined to be
outliers and excluded from the analysis. Independent F-statistics were calculated to determine
variance differences between measures of interest and corresponding T-tests were run to
analyze within and between group differences in six clinical measures for each of the three
genotypes and the two intervention groups. Given the exploratory nature of this study the
significance level (α=0.05) was retained.
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2. Results
3.1 Baseline Differences in Clinical Measures by Genotype
A total of 201 participants completed the study and all results are summarized in Table 2.
Of the six clinical measures examined, three were found to have significant interactions
dependent on KCNS1 genotype, and seem to suggest that the valine risk allele has opposite
effects in patients with chronic musculoskeletal pain compared to those with chronic
neuropathic pain. Participants’ McGill Typical Pain levels were significantly lower in
homogeneous Val/Val individuals than for those with Ile/Ile, but this difference did not
maintain significance when comparing Val/Val to heterogeneous Ile/Val patients. This
suggests that just one copy of the mutated gene is not sufficient to alter an individual’s
musculoskeletal pain experience. Similarly, Val/Val homogeneous individuals scored
significantly higher than Ile/Ile patients. Finally, the valine allele was associated with much
lower pain catastrophizing scores when comparing homogeneous Val/Val to Ile/Ile and to
heterogeneous Ile/Val subjects. These effects were additive, with even just one copy of the
valine allele significantly reducing an individual’s frequency of catastrophizing. The three
additional clinical measures did not show any statistically significant differences regardless of
genotype. All of these findings have been reported previously (French, Bishop, Lieberman,
Atkinson, May, & Naylor, 2014 Submitted to Pain)

3.2 Treatment Response by Genotype
A total of 193 participants also completed a second time point and were included in the
post-treatment analysis. All results are summarized in Tables 3 and 4 and in Figures 2 and 3.
All individuals improved to the same level of physical and mental functioning after either

Comment [a1]: Just give the authors,
paper title, and "Submitted to Pain." in the
reference list.
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treatment and regardless of genotype across all six clinical measures, suggesting both
treatments were successful in alleviating pain-related symptoms. However, it is important to
note that because Val/Val participants already had greater levels of physical and
psychological functioning at baseline, they required a lower degree of improvement compared
to Val/Ile and Ile/Ile individuals to attain the same level of functioning after treatment.
Both Val/Ile and Ile/Ile participants showed statistically significant improvements across
all six clinical measures, whereas Val/Val participants did not have statistically significant
improvements after treatment in their mental or physical composite scores. Furthermore, both
Val/Ile and Ile/Ile individuals improved to the same level of functioning as Val/Val
individuals. This means that both treatments, either psychotherapy with CBT or mailings of
educational materials, are effective in reducing symptoms related to chronic musculoskeletal
pain regardless of KCNS1 genotype, although CBT tended to result in greater improvements
in functioning
Additionally, heterozygous Val/Ile and homozygous Ile/Ile individuals responded
differentially to each intervention, with CBT treatment resulting in greater improvements than
the EDU condition. Individuals with Val/Ile KCNS1 genotype improved significantly more
from CBT than from EDU in Total Pain Experience, PCS, and Catastrophizing scores. This is
in contrast to Ile/Ile individuals, who improved significantly more from CBT than from EDU
in MCS, BDI, and Catastrophizing scores. It is interesting that Ile/Ile participants had the
greatest improvements regarding their psychological symptoms whereas Val/Ile individuals
had larger improvements in their physical functioning, and the effects of these genotypes on
chronic musculoskeletal pain should be investigated further to elucidate the exact nature of
this relationship.
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Within the CBT intervention, Val/Val participants had significantly greater improvements
in depression levels when compared to heterozygous Val/Ile individuals. Conversely, within
the EDU intervention Val/Ile participants had significantly greater improvements in both BDI
and MCS compared to Ile/Ile individuals. Also, it appears as if participants with Ile/Ile and
Val/Ile KCNS1 genotypes may actually be more susceptible to responding to treatment than
those homozygous for the Val mutation. It is interesting that there were no significant
differences between treatments for Val/Val participants across any of the clinical measures,
suggesting these individuals actually improved less from either treatment than those with
Val/Ile and Ile/Ile KCNS1 genotypes. Although this may seem counterintuitive, it could be
explained given that Val/Val individuals started out with higher physical and mental
functioning, and therefore had less room for improvement.
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Table 2. Baseline Differences in Clinical Factors by Genotype
BDI

McGill
Typical

SF-36 PCS

SF-36
MCS

TOPS
TPE

Catastrophizing

16.0
(n=41)

5.9
(n=42)

34.7
(n=42)

42.3
(n=42)

54.1
(n=42)

48.6
(n=41)

0.56

0.78

0.67

0.14

0.47

0.03

0.37

0.02

0.63

0.04

0.30

0.01

Val/Ile

16.7
(n=73)

6.0
(n=76)

34.3
(n=76)

39.0
(n=76)

55.7
(n=76)

52.7
(n=76)

Ile/Ile

18.5
(n=82)

6.6
(n=83)

35.3
(n=83)

37.7
(n=83)

57.5
(n=83)

53.7
(n=83)

Genotype [mean (n)]
Val/Val
p-value vs.
Val/Ile
p-value vs.
Ile/Ile

Table 3. Treatment Response Differences in Clinical Measures by
Genotype
BDI

McGill
Typical

SF-36 PCS

SF-36
MCS

TOPS
TPE

Catastrophizing

9.7
(n=28)

5.3
(n=31)

32.9
(n=26)

46.2
(n=31)

44.4
(n=28)

6.0
(n=32)

0.18

0.25

0.22

0.48

0.22

0.39

0.30

0.44

0.10

0.21

0.10

0.43

Val/Ile

11.1
(n=69)

5.0
(n=74)

32.8
(n=62)

46.1
(n=66)

46.9
(n=61)

5.7
(n=71)

Ile/Ile

10.5
(n=76)

5.2
(n=88)

33.7
(n=73)

44.1
(n=76)

48.6
(n=70)

6.1
(n=87)

Genotype [mean (n)]
Val/Val
p-value vs.
Val/Ile
p-value vs.
Ile/Ile
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Figure 2. Response to Treatment with EDU

Figure 2. Change in Clinical Measures after Treatment with EDU. All participant data for each
genotype was calculated at baseline (TP 1) and after treatment (TP 2). Independent sample T-tests were
used to compare data between genotypes within each clinical measure at TP 1 and TP 2. Independent
sample T-tests were run comparing clinical data scores within each genotype to determine which group
did or did not improve significantly. GG = Val/Val; AG = Val/Ile; AA = Ile/Ile
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Figure 3. Response to Treatment with CBT
Figure 3. Change in Clinical Measures after Treatment with CBT. All participant data for
each genotype was calculated at baseline (TP 1) and after treatment (TP 2). Independent
sample T-tests were used to compare data between genotypes within each clinical measure
at TP 1 and TP 2. Independent sample T-tests were run comparing clinical data scores
within each genotype to determine which group did or did not improve significantly. GG =
Val/Val; AG = Val/Ile; AA = Ile/Ile
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Table 4. Change in Clinical Measures within Genotype Across Interventions
Genotype
(CBT vs.
TPE
PCS
MCS
CATA
McGILL
EDU)
Ile/Ile
-8.9
4.5
-1.0
CBT
-4.1
5.3
-4.4
2.4
-0.8
EDU
-2.1
-0.8
(p=0.07)
(p=0.11)
(p=0.36)
(p=0.02)
(p=0.04)
Val/Ile
5.3
-1.1
-10.9
4.1
-4.3
CBT
5.8
-5.2
-5.1
-0.02
-1.7
EDU
(p=0.43)
(p=0.09)
(p<0.01)
(p<0.01)
(p=0.01)
Val/Val
-6.3
3.4
7.2
-2.4
-0.9
CBT
-8.8
0.42
3.4
-2.9
-0.5
EDU
(p=0.29)
(p=0.15)
(p=0.19)
(p=0.40)
(p=0.24)

BDI

-4.1
0.05
(p=0.01)
-2.6
-3.3
(p=0.29)
-5.6
-1.9
(p=0.07)

Table 4. Average change in clinical measure scores for each genotype within intervention groups
were determined and independent sample T-tests were run to compare the change in clinical
scores for each genotype across interventions.

3. Discussion
The present study investigated KCNS1 effects on the symptomology of chronic
musculoskeletal pain and response to cognitive therapy. KCNS1 is a gene that encodes for a
potassium channel alpha subunit that modulates potassium currents within sensory neurons,
and thus is likely involved in pain signaling (Richardson & Kaczmarek, 2000). Our data
suggest that the common SNP in the KCNS1 gene is associated with perception of pain and
coping in patients with chronic musculoskeletal pain, but with converse effects to those
demonstrated in chronic neuropathic pain (Costigan et al., 2010). Specifically, we
demonstrated that while the valine-to-isoleucine mutation increases one’s risk for
experiencing greater chronic neuropathic pain, it actually seems to protect against chronic
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musculoskeletal pain symptoms, and is associated with less physical pain symptoms and
psychological suffering before treatment in these individuals. However, homogeneous
Val/Val KCNS1 genotype was not associated with a greater response to treatment as was
hypothesized. Rather, Val/Ile and Ile/Ile individuals showed the greatest treatment response,
initially presenting with the greatest amounts of pain and suffering but reaching the same
level of functioning as their Val/Val counterparts after treatment. Although this may speak
more to the fact that Val/Val individuals had higher levels of functioning at baseline, and
required a lower degree of improvement to reach the same functioning as other patients.
This study demonstrated that both CBT and EDU are effective at reducing pain-related
physical and psychological symptoms in individuals with chronic musculoskeletal pain across
all KCNS1 genotypes. After either treatment, all participants reached similar levels of
physical and mental functioning regardless of KCNS1 genotypic variation. This is important
to note, as it suggests psychotherapeutic approaches are a viable treatment option for those
experiencing chronic musculoskeletal pain syndromes, and may reduce potential for longterm health consequences compared to prescription medications. It is of particular interest that
Val/Ile and Ile/Ile participants showed different degrees of response to treatment associated
with their KCNS1 genotypes. Specifically, heterozygous individuals appear to experience
greater improvements related to their physical functioning, whereas homozygous Ile/Ile
participants showed the greatest treatment response in regards to their psychological
suffering. This may suggest wild-type heterozygous Val/Ile KCNS1 genotype, which has one
copy of each allele, may optimize functioning overall. However, the present study is limited
to speculation on this matter and future studies should investigate the effect of Val/Ile and
Ile/Ile KCNS1 genotypes more fully.
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These findings are important because while acute pain is adaptive and protective, chronic
pain is analogous to a disease of the nervous system that results in significant dysfunction
(Woolf, 2010; Young et al., 2012). As such, chronic pain disorders represent a huge public
health concern with significant unmet need for safe and effective treatments. Given the
potentially detrimental effects on quality of life for those experiencing chronic pain, gaining a
better understanding of the underlying mechanisms is essential to provide more efficacious
treatment. Although there remains much to learn, recent literature has illuminated key
findings that may help to explain the shift from acute pain-related inflammation to chronic
musculoskeletal pain.
In acute pain states, inflammatory responses serve to promote sensitivity of the damaged
region so as to allow it to heal. However, chronic pain seems to hijack this system to elicit a
perpetuating cycle of pain signaling. This prolonged response can cause long-term changes in
dorsal horn neurons, which send pain signals to the brain, resulting in unresolved chronic pain
(Woolf & Costigan, 1999). Specifically, following injury there is an initial inflammatory
phase of rehabilitation that results in hypersensitivity of injured cells so as to promote their
recovery (Woolf, 2010; Young et al., 2012). This hypersensitivity results in spontaneous
action potentials and reorganization of synaptic connections in the spinal cord, which may
lead to central sensitization that manifests as pain without a specific noxious stimulus (Woolf,
2010). The synaptic connections that communicate these pain signals can become long-term
pathways, thereby shifting the experience from acute to chronic pain.
Initially, inflammation is characterized by inflammatory cells binding to receptors on
peripheral nociceptor terminals (Ji et al., 2011). These chemical mediators induce
hypersensitivity of the damaged region and increase the firing rates of peripheral nociceptors,

KCNS1 MODULATES CHRONIC MUSCULOSKELETAL PAIN

23

a phenomenon known as peripheral sensitization (Ji et al., 2011). Pain signals are then sent
via two fiber types: large, heavily myelinated A-delta fibers that constitutively transcribe
KCNS1 and produce the immediate sensation of pain, and small, unmyelinated C-fibers that
do not express KCNS1 and produce the slow, second phase of pain (Tsantoulas et al., 2012;
Woolf & Costigan, 1999). Both of these fibers project to second order dorsal horn neurons in
the spinal cord, where they release the excitatory neurotransmitter glutamate and other
neuromodulators (Li et al., 2014; Woolf & Costigan, 1999). Glutamate binds to AMPA and
NMDA receptors on the dorsal horn to stimulate the release of calcium, which in turn
activates protein kinases that phosphorylate AMPA and NMDA, causing up-regulation of
these receptors and hyperexcitability of the membrane (Li et al., 2014). This is referred to as
central sensitization, and serves to prolong the sensation of pain (Ji et al., 2011). If there is
sustained activation of these pathways, excess glutamate release can cause excitotoxicity in
the dorsal horn, resulting in the death of inhibitory neurons and causing potentiated responses
of dorsal horn neurons, a phenomenon called windup (Woolf & Costigan, 1999).
Previous literature has shown that C-fiber activation can rapidly induce both central
sensitization and windup to perpetuate the perception of pain (Woolf & Costigan, 1999). Pain
signaling is further complicated by the fact that C-fiber activation can rapidly change the
sensitivity of large, myelinated A-beta fibers that typically only transduce sensation rather
than pain, causing A-beta fibers to produce painful sensations from non-painful stimuli
(Woolf & Costigan, 1999). A-beta fibers can also sprout new axonal growths into regions of
the spinal cord previously innervated only by pain-signaling C-fibers, resulting in the
perception of pain from non-painful stimuli (Tsantoulas et al., 2012). The overall
hyperexcitability of the pain signaling system results in substantial plasticity, including
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changes in the channel protein transcription and gene expression that can become long-term
changes in chronic pain syndromes (Woolf & Costigan, 1999).
All of these interactions are likely involved in chronic pain syndromes, although the exact
nature of how chronic musculoskeletal pain differs from chronic neuropathic pain remains to
be determined. The fact that the KCNS1 mutation works oppositely in chronic
musculoskeletal pain compared to chronic neuropathic pain suggests that they occur through
separate modalities that are modulated differently by the same potassium channel subunit.
Specifically, one could postulate that if neuropathic pain is caused by long-term maladaptive
sensitization of pain receptors, or nociceptors, musculoskeletal pain may conversely involve
prolonged stimulation of nociceptors (Costigan et al., 2010; Woolf & Costigan, 1999). If this
is the case, it may help explain why KCNS1 genotypic variation exerts different effects on
chronic musculoskeletal pain than it does for chronic neuropathic pain. While Val/Val
individuals tend to experience greater severity of pain and disability in chronic neuropathic
pain, the same cannot be said for Val/Val individuals with chronic musculoskeletal pain.
However, further research is necessary to examine the exact nature of this dynamic.
The potassium channel subunit KCNS1 encodes for serves to inhibit repeated firing of
large, myelinated sensory neurons by maintaining the cell’s resting membrane potential near
the equilibrium potential for potassium (Everill & Kocsis, 1999). Previous literature suggests
that injury-related hyperexcitability may be due to a reduction in potassium currents, which
serve to repolarize the cell out of its refractory period so that it can fire another action
potential (Everill & Kocsis, 1999). If KCNS1 is downregulated in chronic musculoskeletal
pain disorders, as it is for chronic neuropathic pain, downregulation of this potassium channel
allele may result in disinhibition because KCNS1 helps limit excessive neuronal firing.
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However, it is currently unknown whether such downregulation also occurs in chronic
musculoskeletal pain models and the exact effect of KCNS1 modulation depends on what
other subunits are present in the channel and what other channels are present in the membrane
(Richardson & Kaczmarek, 2000; Tsantoulas et al., 2012). Future research should shed some
light on the nature of such mechanisms and explain the different effects seen in chronic
neuropathic versus chronic musculoskeletal pain syndromes.
Clearly, chronic musculoskeletal pain is a complex disorder that involves multiple
interacting factors. Although variation in KCNS1 genotype may modulate pain perception
and/or experience, it is far from the only gene involved and likely has many complex
interactions with other channel subunits, channels, and chemical mediators that produce
specific effects in certain individuals. This is one of the main limitations of the present study,
as examining a single gene encoding for a potassium channel alpha subunit is a definite
oversimplification of the complexity involved in chronic pain syndromes. Future research
should examine the effect of KCNS1 when coexpressed with other potassium channel
subunits to determine the exact nature of its modulation of potassium currents. Additionally,
this study failed to consider epigenetic factors that are likely involved in developing chronic
pain disorders. It would be beneficial for future research to examine such interactions and
shed light on how various lifestyle choices and environmental stimuli modulate pathology in
chronic pain syndromes. These findings warrant future research on the role of potassium
channels in the vast range of phenotypic variation associated with chronic pain disorders and
how to most effectively treat them.
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